Smartkem Engages Anthony Amato to Support Specific Strategic Initiatives

Core Insights - Smartkem has engaged Anthony Amato and his firm, Bridge Associates International Pharmaceutical Consulting (BAIPC), to support its long-term growth initiatives in the electronics sector [1][4][8] - Mr. Amato brings significant experience in life sciences and technology, having previously served as CEO of BioSig Technologies, Inc. and currently being on its Board of Directors [2][4] - The collaboration aims to evaluate and execute strategic opportunities and industry partnerships to enhance shareholder value [3][4] Company Overview - Smartkem is focused on revolutionizing electronics with a new class of transistors using proprietary advanced semiconductor materials, specifically TRUFLEX® semiconductor polymers [5][6] - The company's technology enables low-temperature printing processes compatible with existing manufacturing infrastructure, aimed at delivering low-cost, high-performance displays [5] - Smartkem's semiconductor platform is applicable in various display technologies, including MicroLED, LCD, and AMOLED, as well as in advanced computer and AI chip packaging, sensors, and logic [5] Research and Development - Smartkem operates a research and development facility in Manchester, UK, and provides prototyping services at the Centre for Process Innovation in Sedgefield, UK [6] - The company has a field application office in Hsinchu, Taiwan, to collaborate with The Industrial Technology Research Institute (ITRI) [6] - Smartkem is developing a commercial-scale production process and Electronic Design Automation (EDA) tools to demonstrate the viability of manufacturing a new generation of displays [6] Intellectual Property - The company holds an extensive intellectual property portfolio, including 140 granted patents across 17 patent families, 14 pending patents, and 40 codified trade secrets [7] Strategic Initiatives - On August 28, 2025, Smartkem's Board of Directors authorized management to consider and pursue strategic alternatives involving the company [7]